| Date | Time | Source | |
| 12/07/2021 | 9:00AM | BW | PPD Named to ‘Best Workplaces in Greater China’ for Second Consecutive Year
PPD, Inc. (Nasdaq: PPD) was named one of the “Best Workplaces in Greater China™ 2021” by Great Place to Work® for successfully creating an inclusive workplace experience for employees. PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and... More...>> |
| 12/02/2021 | 9:00AM | BW | PPD Named ‘Best Vaccine CRO of the Year’ in Asia-Pacific
PPD, Inc. (Nasdaq: PPD) was named “Best Vaccine CRO of the Year” at the Asia-Pacific Vaccine Excellence Awards 2021 for its strong presence, extensive experience and quality delivery in the Asia-Pacific (APAC) region. The award recognizes the contract research organization (CRO) operating within Asia that has engaged... More...>> |
| 11/22/2021 | 9:00AM | BW | PPD Wins Multiple Awards at Clinical Researcher of the Year Competition
PPD, Inc. (Nasdaq: PPD) earned numerous honors at the 2021 PharmaTimes Clinical Researcher of the Year-The Americas competition. Two PPD teams won gold, one team won silver and another team took home bronze. PPD clinical researchers also won silver and bronze awards in various individual categories. Last month, PPD was... More...>> |
| 10/27/2021 | 4:10PM | BW | PPD Reports Third Quarter and Year-To-Date 2021 Results
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021. Highlights Net authorizations growth of 12.7% over third quarter 2020 to $1,352.7 million, resulting in a net book-to-bill ratio of 1.19x on a historical basis Ending... More...>> |
| 10/19/2021 | 9:00AM | BW | PPD Named Clinical Research Company of the Year for Second Consecutive Year
PPD, Inc. (Nasdaq: PPD) was named “Clinical Research Company of the Year” at the 2021 PharmaTimes Clinical Researcher of the Year International competition in London. In addition to PPD winning the highest honor, individual PPD clinical researchers won gold and silver in both the Clinical Research Team and Start Up-Singles... More...>> |
| 10/18/2021 | 4:05PM | BW | PPD Announces Third Quarter 2021 Earnings Conference Call
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on... More...>> |
| 10/06/2021 | 9:00AM | BW | Society for Clinical Research Sites Names PPD Winner of Prestigious Eagle Award
PPD, Inc. (Nasdaq: PPD) is the recipient of the 2021 Eagle Award from the Society for Clinical Research Sites (SCRS) for its commitment to advancing clinical research professionalism through strong site partnerships. The award, based on voting by research sites globally, recognizes the contract research organization (CRO... More...>> |
| 09/21/2021 | 9:00AM | BW | PPD Earns Gold Award for Excellence in Employee Learning and Development
PPD, Inc. (Nasdaq: PPD) has been recognized with two global excellence awards for its effective learning programs, honoring the company’s high-performing employee development initiatives supporting delivery of global operational excellence and innovative solutions to customers. For the second consecutive year, PPD received... More...>> |
| 09/01/2021 | 9:00AM | BW | PPD Receives Award Recognizing Employee Talent Development
PPD, Inc. (Nasdaq: PPD) has been recognized as one of the best in the world for its successful employee learning and development programs by the Association for Talent Development (ATD), a global organization that empowers and supports professionals to develop talent in the workplace. PPD is a recipient of the 2021 ATD... More...>> |
| 07/28/2021 | 4:11PM | BW | PPD Reports Second Quarter and Year-To-Date 2021 Results
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the second quarter ended June 30, 2021. Highlights Net authorizations growth of 58.4% over second quarter 2020 to $1,666.4 million, resulting in a net book-to-bill ratio of 1.55x on a historical basis Ending... More...>> |
| 07/20/2021 | 9:00AM | BW | PPD Recognized as a Best Place to Work in Asia
PPD, Inc. (Nasdaq: PPD) has been named one of the Best Workplaces in Asia™ by Great Place to Work®, a global authority on high-trust, high-performance workplace cultures. PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services... More...>> |
| 07/12/2021 | 4:10PM | BW | PPD Announces Second Quarter 2021 Earnings Conference Call
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Thursday, July 29, 2021, at 7 a.m. (U.S. Eastern Time) to discuss its second quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to... More...>> |
| 05/27/2021 | 9:00AM | BW | PPD Named ‘Most Innovative CRO’ by Triangle Business Journal
Honors PPD’s development and implementation of innovative customer solutions during COVID-19 pandemic PPD, Inc. (Nasdaq: PPD) has been named “Most Innovative CRO” by North Carolina’s Triangle Business Journal, recognizing the global contract research organization’s strong performance in a year shaped by the COVID-19... More...>> |
| 05/24/2021 | 9:00AM | BW | PPD Opens Multipurpose Clinical Research Laboratory in Suzhou, China
Offers bioanalytical, biomarker and vaccine sciences services for global and China-based customers PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, held a grand opening ceremony for its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies... More...>> |
| 05/20/2021 | 9:00PM | BW | PPD百時益位於蘇州的多功能臨床研究實驗室正式投入運營
為中國及全球製藥客戶提供一站式的生物分析，生物標誌物和疫苗研究等實驗室服務 (美國商業資訊)--全球領先的CRO(合同研究組織）PPD百時益位於中國蘇州實驗室在5月20日舉辦了盛大的開業典禮，宣告著這座新的多功能實驗室正式投入運營， 以支持中國本土和其他全球的醫藥企業在中國的研究項目。該實驗室位於江蘇省蘇州市高新區，面積達到6224平米的，將提供包括生物分析，生物標誌物和疫苗研究等實驗室服務，支持藥物開發各個階段的試驗。公司預計由於新實驗室的設立，在未來三年將增加約300個專業崗位。此外，這座新的多功能實驗室也是公司現有的於2015年所設立的上海中心實驗室的擴充。... More...>> |
| 05/20/2021 | 9:00PM | BW | PPD百时益位于苏州的多功能临床研究实验室正式投入运营
为中国及全球制药客户提供一站式的生物分析，生物标志物和疫苗研究等实验室服务 (美国商业资讯)--全球领先的CRO(合同研究组织）PPD百时益位于中国苏州实验室在5月20日举办了盛大的开业典礼，宣告着这座新的多功能实验室正式投入运营， 以支持中国本土和其他全球的医药企业在中国的研究项目。该实验室位于江苏省苏州市高新区，面积达到6224平米的，将提供包括生物分析，生物标志物和疫苗研究等实验室服务，支持药物开发各个阶段的试验。公司预计由于新实验室的设立，在未来三年将增加约300个专业岗位。此外，这座新的多功能实验室也是公司现有的于2015年所设立的上海中心实验室的扩充。... More...>> |
| 05/20/2021 | 9:00AM | BW | CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year
PPD, Inc. (Nasdaq: PPD) has been recognized for excellence in the CRO Leadership Awards for the 10th consecutive year, earning praise for its clinical research capabilities and customer compatibility in a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines... More...>> |
| 05/06/2021 | 8:30AM | BW | PPD Named “Best CRO” at Vaccine Industry Excellence Awards
PPD, Inc. (Nasdaq: PPD) was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress. Accelerated Enrollment Solutions (AES), a business of PPD, received the honor of “highly commended” in the category of “Best Clinical Trial... More...>> |
| 04/28/2021 | 9:00AM | BW | PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities
Adding cell and gene therapy capabilities to support growing customer need PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, is expanding its Athlone, Ireland, GMP (good manufacturing practices) laboratory, significantly increasing the size of its current facility and adding cell and gene therapy... More...>> |
| 04/27/2021 | 4:13PM | BW | PPD Reports First Quarter 2021 Results
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the first quarter ended March 31, 2021. Highlights Net authorizations growth of 39.3% over first quarter 2020 to $1,481.6 million, resulting in a net book-to-bill ratio of 1.46x on a historical basis Ending... More...>> |